What kind of people are "engines"? Studies show that they are more likely to be psychopaths, sadists, and narcissists.

Published Date: 17 Feb 2023

Online dating has revolutionized dating by creating more opportunities to meet partners than ever before.

Read Full News

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

6 Psychiatry Headlines You Missed in January 2026

FDA Examines Generative AI in Psychiatry, With Hans Eriksson, MD, PhD Hans Eriksson, MD, PhD

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Utilizing Alcohol Use Disorder Pharmacotherapy in Hepatology, With Hersh Shroff, MD, MPA Hersh Shroff, MD, MPA

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

Todays Updates

How Doctors Can Thrive in a World of Constant Interruption

A steady deluge of interruptions, demands, and distractions drain physicians and raise the risk of errors. Here’s how to protect your focus.

Study Finds Microplastics Near Tumors; Experts Doubt Results

Using LDIR, O PTIR, Py GC/MS, and SEM, researchers quantified MNPs in 191 brain samples, but experts question the unusually high particle masses and urge methodological validation.

Todays Updates

How Doctors Can Thrive in a World of Constant Interruption

A steady deluge of interruptions, demands, and distractions drain physicians and raise the risk of errors. Here’s how to protect your focus.

Study Finds Microplastics Near Tumors; Experts Doubt Results

Using LDIR, O PTIR, Py GC/MS, and SEM, researchers quantified MNPs in 191 brain samples, but experts question the unusually high particle masses and urge methodological validation.

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

News All Time

Psychiatry in 2025: Year in Review

Psychiatry in 2025: Year in Review

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

4 Psychiatry Headlines You Missed in November 2025

4 Psychiatry Headlines You Missed in November 2025

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Single Dose of MM120 (LSD) Shows Lasting Anxiety Reduction in GAD: Phase 2b Results Chelsie Derman

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

FDA Releases CRL Detailing Safety Concerns for MDMA-Assisted Therapy in PTSD Chelsie Derman

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

Atopic Eczema Linked to Suicidal Ideation in Global Study of 30,000 Adults Chelsie Derman

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

FDA Initiates Acetaminophen Label Change, Leucovorin Approval for Cerebral Folate Deficiency Abigail Brooks, MA

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

Daily Ammoxetine at 40, 60 mg Outperforms Placebo for MDD in Phase 2 Trial Chelsie Derman

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

APhA, Coalition of Autism Scientists Cite Insufficient Data to Support Acetaminophen, Autism Link Abigail Brooks, MA

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

5 Psychiatry Headlines You Missed in September 2025 Chelsie Derman

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Recommended News For You

Nodal Response After Chemo Helps Tailor Breast Radiotherapy

Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries

Home Screening Appeals to Women Facing Healthcare Barriers

Triplet Therapy Improves Posttransplant Outcomes in Myeloma

Survey shows cancer anxiety has impact well beyond the individual diagnosed

A new drug delivery system may help patients with a rare eye cancer

New drug combination shows good results in patients with HPV-negative head and neck cancer

Recommended Articles For You

Breaking Down Amyloidosis: Understanding the Disease  

All You Need to Know About Mesna: The Ultimate Guide 

Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells 

How Bispecific Antibodies are Redefining Medical Oncology in the US - A 2025 Review 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Indoor hydroponic gardening can improve mental health and quality of life for cancer patients

2.

The origin of BPH and prostate cancer in different prostate zones and the impact on the incidence of prostate cancer

3.

New BiTE Agent for Small Cell Lung Cancer Approved by the FDA.

4.

Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation

5.

CAR T cells improve patients' quality of life: a study

1.

Fresh Frozen Plasma: Its Role in Treating Trauma and Bleeding Disorders

2.

Unraveling the Mystery of Non-Caseating Granulomas: A Comprehensive Guide

3.

Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights

4.

Methemoglobinemia in OR & ICU: Pathophysiology, Detection, and Management Review

5.

Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

3.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

5.

Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot